Cost Analysis of Albumin-Bound Paclitaxel vs PaclitaxelCost Analysis of Albumin-Bound Paclitaxel vs Paclitaxel
Is standard paclitaxel more cost-effective than nanoparticle albumin-bound paclitaxel? Expert Review of Pharmacoeconomics & Outcomes Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Celgene raises full-year outlook on strong cancer drug sales
(Reuters) - Biotechnology firm Celgene Corp raised its full-year earnings forecast for the second time in three months after it reported a quarterly profit above analysts' estimates, as its cancer drugs, Revlimid and Abraxane, continued to post strong sales growth. (Source: Reuters: Health)
Source: Reuters: Health - July 25, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Mother Nature talks nanotech: cancer drugs | Holly Cave
In a new series about nanotechnology, Mother Nature goes head-to-head with a scientist. This week: cancer drugsNanoparticles – particles as little as a millionth of a millimetre wide made from materials such as polymers, metals and graphene – have properties and behaviours that are being used to carry drugs and target them at cancer cells. So tell me: what's your beef? Well that's typical, isn't it? I come up with a simple way to keep you humans from completely overpopulating the planet without too much fuss (epidemics and natural disasters are so OTT), and scientists have to go meddling. Not that interfering is anythi...
Source: Guardian Unlimited Science - July 12, 2013 Category: Science Authors: Holly Cave Tags: Blogposts Biology Health guardian.co.uk Medical research Nanotechnology Society Cancer Chemistry Biochemistry and molecular biology Science Source Type: news
nab-paclitaxel promising for Japanese NSCLC patients
Phase III trial results support the use of albumin-bound paclitaxel plus carboplatin as a first-line treatment for Japanese patients with advanced non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - June 1, 2013 Category: Cancer & Oncology Source Type: news
nab-paclitaxel promising for Japanese NSCLC patients
Phase III trial results support the use of albumin-bound paclitaxel plus carboplatin as a first-line treatment for Japanese patients with advanced non-small-cell lung cancer. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - June 1, 2013 Category: Cancer & Oncology Source Type: news
nab-paclitaxel promising for Japanese NSCLC patients
Phase III trial results support the use of albumin-bound paclitaxel plus carboplatin as a first-line treatment for Japanese patients with advanced non-small-cell lung cancer. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - May 30, 2013 Category: Respiratory Medicine Source Type: news
A New Delivery for Cancer Drugs
Scott McNeil, director of the Nanotechnology Characterization Lab at the Frederick National Laboratory for Cancer Research
The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited. “It was so toxic that it caused death,” and researchers gave up on it, explains Scott McNeil, director of the Nanotechnology Characterization Lab at the Frederick National Laboratory for Cancer Research.
That was back in the 1990s. Today, TNF-alpha is a...
Source: NCI Benchmarks - May 7, 2013 Category: Cancer & Oncology Authors: admin Tags: cancer nanotechnology Source Type: news
Celgene's Abraxane Scores a Win Against Tough Pancreatic Cancer
Celgene Corp.'s nanoparticle formulation of paclitaxel, Abraxane, when added to standard of care gemcitabine, extended the life of advanced pancreatic cancer patients by 59% at one year and more than doubled... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 30, 2013 Category: Cancer & Oncology Source Type: news
Abraxane Improves Survival Among Pancreatic Cancer Patients
Celegene Corp's drug Abraxane (paclitaxel protein-bound particles for injectable suspension) was found to be effective at improving overall survival among pancreatic cancer patients when combined with chemotherapy, according to results from the drug's phase III clinical trial. Even though Pancreatic cancer is a relatively uncommon form of cancer - making up only 2.1% cancer cases - it is one of the leading causes of cancer related deaths killing around 38,000 people in the U.S. every year... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news
Drug Combination Extends Pancreatic Cancer Patient Survival
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study was led by physicians from Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news
Survival benefit reported in MPACT study of Abraxane® in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer
Source: BioSpace
Area: News
Celgene International Sàrl has announced that its phase III trial of Abraxane® (paclitaxel albumin-bound bound particles) in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone (median of 8.5 vs. 6.7 months; hazard ratio, 0.72, p=0.000015).
The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study is an open-label, study of 861 metastatic pancreatic cancer patients who were randomised to receive either Abraxan...
Source: NeLM - News - January 24, 2013 Category: Drugs & Pharmacology Source Type: news
First drug combination for pancreatic cancer increases survival rates
A Phase III clinical trial in the US has shown that Abraxane plus gemcitabine is the first combination of drugs to extend the survival of late-stage pancreatic cancer patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 24, 2013 Category: Pharmaceuticals Source Type: news
A Drug Shows Promise In Treating Pancreatic Cancer
Celgene’s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, but the gains were not as big as expected. (Source: NYT Health)
Source: NYT Health - January 23, 2013 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Pancreatic Cancer Clinical Trials Drugs (Pharmaceuticals) Roche Holding A G RHHBY Other OTC Abraxane Celgene Corporation CELG NASDAQ Abraxis BioScience, Incorporated ABBI NASDAQ Source Type: news
Celgene's Abraxane Extends Life By 1.8 Months In Advanced Pancreatic Cancer
Abraxane, a cancer chemotherapy made by Celgene, slowed tumor growth and cut the risk of death in patients with advanced pancreatic cancer, according to results that will be presented at a conference on gastrointestinal tumors being held by the American Society of Clinical Oncology. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 22, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
Celgene's Abraxane increases survival in pancreatic cancer
(Reuters) - Celgene Corp said its Abraxane drug helped patients with advanced pancreatic cancer live an average of two months longer than chemotherapy and significantly increased the percentage of those who survived with the disease for up to two years, according to a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
